LifeCycle Pharma A/S - Report Pursuant to the Danish Securities Trading Act, Section 28 (a)
31-03-10 kl. 31/3 2010 00:02 | Veloxis Pharmaceuticals 0,90 (+4,65%)
Se flere nyheder om Veloxis Pharmaceuticals
Company Announcement no. 5/2010
To: NASDAQ OMX Copenhagen Hørsholm, Denmark, March 30, 2010
LifeCycle Pharma A/S - Report Pursuant to the Danish Securities Trading Act,
Section 28 (a)
Hørsholm, Denmark, March 30, 2010; Pursuant to the Danish Securities Trading
Act, Section 28(a), LifeCycle Pharma A/S (OMX: LCP) is required on a daily
basis, to make public transactions in LifeCycle Pharma shares and related
securities by persons discharging managerial responsibilities and persons /
companies closely associated with these.
Name William J. Polvino
Reason for reporting President & CEO
Issuer and ID code/ISIN LifeCycle Pharma A/S / DK0060048148
Type of transaction Purchase of shares
Date of transaction March 30, 2009
Relevant market NASDAQ OMX Copenhagen
Number of traded securities 20,000
Market value DKK 103,000
For more information, please contact:
LifeCycle Pharma A/S
Peter Schøtt Knudsen
Head of Investor Relations
Phone: + 45 2055 3817
Email: [email protected]
30mar2010 - lifecycle pharma - report pursuant to the danish securities trading act section 28_a_.pdf
Skriv en kommentarer til denne artikel:
Send kommentar
| PRIS | 0,90 |
|---|---|
| ÆNDRING | +0,04 (+4,65%) |
| ÅBEN | 0,87 |
| SIDSTE LUK | 0,86 |
| DEBAT | - |
 |
